ABSTRACT
Primary adenocarcinoma of the rectovaginal septum is an extremely rare disease and have been reported only twenty cases all over the world, and that considered arise from endometriosis in most of the cases. We report two cases, 53-year-old and 48-year-old women, of primary adenocarcinoma of the rectovaginal septum without endometriosis. This tumor is important to consider one of the pelvic tumors. We discuss the clinical findings, examination findings and pathogenesis of this tumor.
Subject(s)
Adenocarcinoma/pathology , Rectal Neoplasms/pathology , Vaginal Neoplasms/pathology , Female , Humans , Middle AgedABSTRACT
A 70-year-old man with abdominal pain and anemia was diagnosed with duodenal cancer upon upper gastrointestinal endoscopy and biopsy. Pancreatoduodenectomy was performed. Pathological findings were duodenal cancer, T 4 SI (Panc) N0P0V0A0H0. Three months after operation, abdominal CT showed multiple liver metastasis. He then underwent combined chemotherapy consisting of two weeks administration of S-1 (80 mg/body) followed by one week rest and injections of docetaxel (40 mg/body) every three weeks as one course. Metastatic tumors were gradually reduced and successfully controlled,and there was no other recurrence until he died about three years later of another illness. Combined S-1 and docetaxel chemotherapy is known to be effective for esophageal cancer, gastric cancer and other digestive cancer, as well as for duodenal cancer.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Duodenal Neoplasms/pathology , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Aged , Antineoplastic Agents/administration & dosage , Docetaxel , Drug Combinations , Duodenal Neoplasms/drug therapy , Duodenal Neoplasms/surgery , Humans , Male , Oxonic Acid/administration & dosage , Taxoids/administration & dosage , Tegafur/administration & dosageABSTRACT
Tokai Medical Products developed an intra-aortic balloon pumping (IABP) balloon catheter with the following unique characteristics: the balloon can be applied to any patient irrespective of their physical size, and is therefore suitable for Japanese patients of small stature; a long soft tip is used, which is designed to avoid damage to blood vessels; the size of the catheter is reduced to 7 Fr, and the catheter can be used as a multifunctional balloon catheter, such as the Yoshioka type, that allows simultaneous percutaneous coronary intervention (PCI). The safety of this catheter has been proven in scientific studies. In this review, we report the development of our IABP balloon catheter and give an outline of its characteristics.
Subject(s)
Catheterization/instrumentation , Catheters, Indwelling , Intra-Aortic Balloon Pumping/instrumentation , Adult , Aorta, Abdominal/diagnostic imaging , Cardiovascular Diseases/therapy , Catheters, Indwelling/adverse effects , Catheters, Indwelling/classification , Child , Equipment Design , Humans , Intra-Aortic Balloon Pumping/adverse effects , Japan , RadiographyABSTRACT
OBJECTIVE: Docetaxel (DOC) is a novel microtubule polymerizing agent, with superior antiproliferative properties as compared to paclitaxel. DOC is therefore a potential therapeutic tool for the prevention of restenosis following angioplasty. However, DOC has systemic toxicity such as leukocytopenia, which occurs in a dose-dependent manner. To minimize such adverse effects, we carried out local delivery of low-dose DOC directly to injured vessel sites. METHODS: The rabbit iliac artery was denuded, and then DOC (2 mg) or control vehicle was administered locally 20 min, via a local drug delivery catheter. RESULTS: The levels of DOC in the plasma were within ng/ml range, eliminating hematopoietic side effects. Seven days after the local delivery (DOC: n=4, control: n=4), DOC decreased the number of Ki-67-labeled cells in the intima (DOC: 22 +/-10 vs. control: 66 +/- 18 cells/mm(2), P<0.01), indicating a decreased proliferative activity. At 28 days (DOC: n=8, control: n=8), computer-assisted morphometric analysis demonstrated that DOC significantly reduced the intimal area (DOC: 0.15 +/- 0.13 vs. control: 0.70 +/- 0.13 mm(2), P<0.01). There was also a decrease in medial area in the DOC-treated vessels (DOC: 0.62 +/- 0.17 vs. control: 1.13 +/- 0.38 mm(2), P<0.01). CONCLUSIONS: Local delivery of DOC, even after a single low-dose administration, effectively inhibits neointimal hyperplasia. Such administration is associated with a minimal likelihood of systemic adverse effects (leukocytopenia), but potentially induces local toxicity (a decrease in medial wall thickness) due to extensive cytotoxic effect.
